Prognostic factors for patients with advanced seminoma treated with platinum-based chemotherapy.

2.50
Hdl Handle:
http://hdl.handle.net/10541/94752
Title:
Prognostic factors for patients with advanced seminoma treated with platinum-based chemotherapy.
Authors:
Fosså, S; Oliver, R; Stenning, S; Horwich, A; Wilkinson, P; Read, G; Mead, G; Roberts, J; Rustin, G; Cullen, M; Kaye, Stan B; Harland, S; Cook, P
Abstract:
Prognostic factors for 3-year progression-free survival (PFS) were defined in 286 patients with advanced seminoma treated with cisplatin-based chemotherapy at 10 European oncology units (no prior treatment: 236; prior radiotherapy: 50). Previously irradiated patients displayed a 69% PFS as compared to 87% in those presenting with advanced seminoma at the time of diagnosis (P = 0.009). In the univariate analysis, the extent and site of disease before chemotherapy and the level of serum LDH (< 2.0 versus > or = 2.0 x upper limit of normal) correlated with PFS in previously non-irradiated patients, but not in patients with prior radiotherapy. The multivariate analysis was, therefore, restricted to previously non-irradiated patients. The presence of non-pulmonary visceral metastases and a serum LDH level of > or = 2 x normal (N) proved to be independent prognostic factors. Based on these variables, two prognostic models were constructed and validated in an external data set of 166 comparable patients. For clinical use, Model 2 is recommended. The good-prognosis group comprises non-irradiated patients with stage II seminoma and any LDH level at presentation, or stage III and IV patients (with lung metastases only) whose serum LDH level is < 2 x N. These patients display a 94% 3-year PFS. The poor prognosis group includes all other patients with a 56% PFS. With this prognostic model, individualisation of the therapeutic approach may be considered in patients with advanced seminoma and a high risk of chemotherapy-related toxicity.
Affiliation:
Norwegian Radium Hospital, Department of Medical Oncology, Montebello, Oslo, Norway.
Citation:
Prognostic factors for patients with advanced seminoma treated with platinum-based chemotherapy. 1997, 33 (9):1380-7 Eur J Cancer
Journal:
European Journal of Cancer
Issue Date:
Aug-1997
URI:
http://hdl.handle.net/10541/94752
DOI:
10.1016/S0959-8049(96)00425-X
PubMed ID:
9337678
Type:
Article
Language:
en
ISSN:
0959-8049
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorFosså, Sen
dc.contributor.authorOliver, Ren
dc.contributor.authorStenning, Sen
dc.contributor.authorHorwich, Aen
dc.contributor.authorWilkinson, Pen
dc.contributor.authorRead, Gen
dc.contributor.authorMead, Gen
dc.contributor.authorRoberts, Jen
dc.contributor.authorRustin, Gen
dc.contributor.authorCullen, Men
dc.contributor.authorKaye, Stan Ben
dc.contributor.authorHarland, Sen
dc.contributor.authorCook, Pen
dc.date.accessioned2010-03-23T17:06:11Z-
dc.date.available2010-03-23T17:06:11Z-
dc.date.issued1997-08-
dc.identifier.citationPrognostic factors for patients with advanced seminoma treated with platinum-based chemotherapy. 1997, 33 (9):1380-7 Eur J Canceren
dc.identifier.issn0959-8049-
dc.identifier.pmid9337678-
dc.identifier.doi10.1016/S0959-8049(96)00425-X-
dc.identifier.urihttp://hdl.handle.net/10541/94752-
dc.description.abstractPrognostic factors for 3-year progression-free survival (PFS) were defined in 286 patients with advanced seminoma treated with cisplatin-based chemotherapy at 10 European oncology units (no prior treatment: 236; prior radiotherapy: 50). Previously irradiated patients displayed a 69% PFS as compared to 87% in those presenting with advanced seminoma at the time of diagnosis (P = 0.009). In the univariate analysis, the extent and site of disease before chemotherapy and the level of serum LDH (< 2.0 versus > or = 2.0 x upper limit of normal) correlated with PFS in previously non-irradiated patients, but not in patients with prior radiotherapy. The multivariate analysis was, therefore, restricted to previously non-irradiated patients. The presence of non-pulmonary visceral metastases and a serum LDH level of > or = 2 x normal (N) proved to be independent prognostic factors. Based on these variables, two prognostic models were constructed and validated in an external data set of 166 comparable patients. For clinical use, Model 2 is recommended. The good-prognosis group comprises non-irradiated patients with stage II seminoma and any LDH level at presentation, or stage III and IV patients (with lung metastases only) whose serum LDH level is < 2 x N. These patients display a 94% 3-year PFS. The poor prognosis group includes all other patients with a 56% PFS. With this prognostic model, individualisation of the therapeutic approach may be considered in patients with advanced seminoma and a high risk of chemotherapy-related toxicity.en
dc.language.isoenen
dc.subjectTesticular Canceren
dc.subjectBiological Tumour Markersen
dc.subject.meshAdult-
dc.subject.meshAnalysis of Variance-
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols-
dc.subject.meshCisplatin-
dc.subject.meshDisease-Free Survival-
dc.subject.meshHumans-
dc.subject.meshL-Lactate Dehydrogenase-
dc.subject.meshMale-
dc.subject.meshMiddle Aged-
dc.subject.meshPrognosis-
dc.subject.meshRetrospective Studies-
dc.subject.meshRisk Factors-
dc.subject.meshSeminoma-
dc.subject.meshTesticular Neoplasms-
dc.subject.meshTumor Markers, Biological-
dc.titlePrognostic factors for patients with advanced seminoma treated with platinum-based chemotherapy.en
dc.typeArticleen
dc.contributor.departmentNorwegian Radium Hospital, Department of Medical Oncology, Montebello, Oslo, Norway.en
dc.identifier.journalEuropean Journal of Canceren

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.